These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 28223856)
1. Uncertainties around incretin-based therapies: A literature review. Al Tulaihi B; Alhabib S Saudi Pharm J; 2017 Jan; 25(1):1-7. PubMed ID: 28223856 [No Abstract] [Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
3. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Nauck M Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970 [TBL] [Abstract][Full Text] [Related]
4. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878 [TBL] [Abstract][Full Text] [Related]
5. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Campbell RK Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040 [TBL] [Abstract][Full Text] [Related]
6. Enhancing incretin action for the treatment of type 2 diabetes. Drucker DJ Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604 [TBL] [Abstract][Full Text] [Related]
7. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. Cornell S J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069 [TBL] [Abstract][Full Text] [Related]
8. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Deacon CF; Mannucci E; Ahrén B Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Aroda VR; Henry RR; Han J; Huang W; DeYoung MB; Darsow T; Hoogwerf BJ Clin Ther; 2012 Jun; 34(6):1247-1258.e22. PubMed ID: 22608780 [TBL] [Abstract][Full Text] [Related]
11. Incretin hormones: Their role in health and disease. Nauck MA; Meier JJ Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588 [TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Hemmingsen B; Sonne DP; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279 [TBL] [Abstract][Full Text] [Related]
13. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR? Mora PF; Johnson EL Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769 [TBL] [Abstract][Full Text] [Related]
14. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. Seino Y; Yabe D J Diabetes Investig; 2013 Mar; 4(2):108-30. PubMed ID: 24843641 [TBL] [Abstract][Full Text] [Related]
15. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Ferrari F; Moretti A; Villa RF Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147 [TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide. Nauck MA; Mirna AEA; Quast DR Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380 [TBL] [Abstract][Full Text] [Related]
18. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Nauck MA; Quast DR; Wefers J; Pfeiffer AFH Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013 [TBL] [Abstract][Full Text] [Related]
19. An updated review on cancer risk associated with incretin mimetics and enhancers. Tseng CH; Lee KY; Tseng FH J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196 [TBL] [Abstract][Full Text] [Related]
20. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Gilbert MP; Pratley RE Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]